Piper Sandler started coverage on shares of enGene (NASDAQ:ENGN - Free Report) in a research note published on Tuesday, MarketBeat.com reports. The brokerage issued an overweight rating and a $26.00 price objective on the stock.
Several other research analysts also recently commented on ENGN. Raymond James initiated coverage on shares of enGene in a report on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 target price on the stock. Citizens Jmp upgraded shares of enGene to a "strong-buy" rating in a report on Monday, November 18th. HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They issued a "buy" rating and a $25.00 target price on the stock. UBS Group downgraded shares of enGene from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $34.00 to $7.00 in a report on Friday, February 14th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $18.00 target price on shares of enGene in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $25.89.
Read Our Latest Stock Report on ENGN
enGene Stock Up 2.0 %
Shares of ENGN stock traded up $0.12 on Tuesday, hitting $6.24. The company's stock had a trading volume of 83,747 shares, compared to its average volume of 144,081. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The firm's fifty day moving average price is $6.76 and its 200-day moving average price is $7.20. The stock has a market capitalization of $276.07 million, a price-to-earnings ratio of -10.76 and a beta of -0.65.
enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. Research analysts anticipate that enGene will post -1.56 EPS for the current year.
Institutional Trading of enGene
Several institutional investors have recently made changes to their positions in the business. Fcpm Iii Services B.V. boosted its position in shares of enGene by 11.0% during the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock valued at $64,057,000 after acquiring an additional 954,610 shares in the last quarter. VR Adviser LLC boosted its position in enGene by 41.5% in the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock valued at $33,559,000 after buying an additional 1,480,573 shares in the last quarter. Deep Track Capital LP lifted its position in shares of enGene by 74.8% during the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock worth $30,308,000 after purchasing an additional 1,949,942 shares in the last quarter. Blue Owl Capital Holdings LP lifted its position in shares of enGene by 3.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after purchasing an additional 101,006 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in shares of enGene by 84.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company's stock worth $8,145,000 after purchasing an additional 561,797 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.
enGene Company Profile
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
